FDA grants traditional approval to tepotinib for MET exon 14 NSCLC
The agency approved the EMD Serono drug, marketed as Tepmetko, on February 15, 2024 for adults with metastatic non-small cell lung cancer carrying MET exon 14 skipping alterations.
The Food and Drug Administration approved tepotinib on February 15, 2024, granting traditional approval to the drug for a specific population of lung cancer patients. The agency granted traditional approval to tepotinib, marketed as Tepmetko by EMD Serono, Inc., for adult patients with metastatic non-small cell lung cancer harboring mesenchymal-epithelial transition exon 14 skipping alterations.1
The source does not provide additional detail on the trial data, dosing, or prior regulatory history that supported this approval. It also does not state whether this approval followed any earlier accelerated pathway clearance for the drug.
Readers tracking this approval should note that the available documentation confirms only the traditional approval date and the specific patient population covered, without further context on clinical trial endpoints or regulatory timeline preceding the February 2024 action.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.